ADARx Pharmaceuticals Appoints Dr. Chris Storgard as Chief Medical Officer
02 avr. 2024 09h05 HE
|
ADARx Pharmaceuticals
ADARx Pharmaceuticals, next-generation RNA therapeutics developer, appoints Dr. Chris Storgard as Chief Medical Officer
Lyophilization Services for Biopharmaceuticals Market worth $3.58 Billion by 2028 - Exclusive Report by The Insight Partners
04 sept. 2023 10h08 HE
|
The Insight Partners
Pune, India, Sept. 04, 2023 (GLOBE NEWSWIRE) -- Lyophilization is a process of isolating a solid substance from a solution. It is also known as freeze-drying is a process. The process is carried by...
SiSaf Appoints Nikos Tzagkarakis in the New Role of Chief A.I. Officer
13 juil. 2023 04h00 HE
|
SiSaf Ltd
GUILDFORD, England, July 13, 2023 (GLOBE NEWSWIRE) -- RNA delivery and therapeutics company SiSaf Ltd announces that it has appointed Nikos Tzagkarakis in the newly created role of Chief A.I....
Ractigen Therapeutics Receives FDA Orphan Drug Designation for the novel oligonucleotide conjugate RAG-17 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
03 mars 2023 09h00 HE
|
Ractigen Therapeutics
JIANGSU, China, March 03, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to RAG-17, a novel siRNA...
Ractigen Therapeutics Announces the Appointment of Harri Järveläinen as Chief Operating Officer
09 janv. 2023 07h00 HE
|
Ractigen Therapeutics
SUZHOU, China, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, Inc. announced today that Dr. Harri Järveläinen has been appointed Chief Operating Officer of the Company. "I am thrilled to...
invIOs to present at Biotech Showcase
14 déc. 2022 08h00 HE
|
invIOs GmbH
VIENNA, Austria, Dec. 14, 2022 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that CEO Peter...
Vir Biotechnology to Host a Virtual Hepatitis Portfolio R&D Day
13 avr. 2022 16h02 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, April 13, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will host a virtual Hepatitis Portfolio R&D Day for the investment...
Silence Therapeutics Welcomes Deep Track Capital as New Shareholder
01 déc. 2021 07h00 HE
|
Silence Therapeutics plc
1 December 2021 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA)...
Silence Therapeutics Begins Exclusive Nasdaq Trading
30 nov. 2021 07h00 HE
|
Silence Therapeutics plc
Silence Therapeutics Begins Exclusive Nasdaq Trading 30 November 2021 LONDON, Silence Therapeutics plc, Nasdaq:SLN ("Silence" or "the Company"), a leader in the discovery, development and...
Silence Therapeutics to Present at Jefferies London Healthcare Conference
11 nov. 2021 07h00 HE
|
Silence Therapeutics plc
Silence Therapeutics to Present at Jefferies London Healthcare Conference 11 November 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the...